TRPM2 protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction via modulating autophagy

Background: Cisplatin is a widely used anti-tumor agent but its use is frequently limited by nephrotoxicity. Transient receptor potential melastatin 2 (TRPM2) is a non-selective cation channel which is generally viewed as a sensor of oxidative stress, and increasing evidence supports its link with a...

Full description

Saved in:
Bibliographic Details
Published in:Theranostics 2023-01, Vol.13 (13), p.4356-4375
Main Authors: Yu, Binfeng, Jin, Lini, Yao, Xi, Zhang, Yi, Zhang, Gensheng, Wang, Fangqin, Su, Xinwan, Fang, Qiuyuan, Xiao, Liang, Yang, Yi, Jiang, Lin-Hua, Chen, Jianghua, Yang, Wei, Lin, Weiqiang, Han, Fei
Format: Article
Language:English
Subjects:
Research Paper
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c356t-b32367a4fe9db6a9399b5da95a01cb096f594f1734a1904e4fb6964d5bda080c3
cites
container_end_page 4375
container_issue 13
container_start_page 4356
container_title Theranostics
container_volume 13
creator Yu, Binfeng
Jin, Lini
Yao, Xi
Zhang, Yi
Zhang, Gensheng
Wang, Fangqin
Su, Xinwan
Fang, Qiuyuan
Xiao, Liang
Yang, Yi
Jiang, Lin-Hua
Chen, Jianghua
Yang, Wei
Lin, Weiqiang
Han, Fei
description Background: Cisplatin is a widely used anti-tumor agent but its use is frequently limited by nephrotoxicity. Transient receptor potential melastatin 2 (TRPM2) is a non-selective cation channel which is generally viewed as a sensor of oxidative stress, and increasing evidence supports its link with autophagy, a critical process for organelle homeostasis. Methods: Cisplatin-induced cell injury and mitochondrial damage were both assessed in WT and Trpm2- knockout mice and primary cells. RNA sequencing, immunofluorescence staining, immunoblotting and flowcytometry were applied to interpret the mechanism of TRPM2 in cisplatin nephrotoxicity. Results: Knockout of TRPM2 exacerbates renal dysfunction, tubular injury and cell apoptosis in a model of acute kidney injury (AKI) induced by treatment with cisplatin. Cisplatin-caused tubular mitochondrial damage is aggravated in TRPM2-deficient mice and cells and, conversely, alleviated by treatment with Mito-TEMPO, a mitochondrial ROS scavenger. TRPM2 deficiency hinders cisplatin-induced autophagy via blockage of Ca 2+ influx and subsequent up-regulation of AKT-mTOR signaling. Consistently, cisplatin-induced tubular mitochondrial damage, cell apoptosis and renal dysfunction in TRPM2-deficient mice are mitigated by treatment with a mTOR inhibitor. Conclusion: Our results suggest that the TRPM2 channel plays a protective role in cisplatin-induced AKI via modulating the Ca 2+ -AKT-mTOR signaling pathway and autophagy, providing novel insights into the pathogenesis of kidney injury.
doi_str_mv 10.7150/thno.84655
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10465213</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2859604663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-b32367a4fe9db6a9399b5da95a01cb096f594f1734a1904e4fb6964d5bda080c3</originalsourceid><addsrcrecordid>eNpVkU1LJDEQhpvFBWX04i_IcRHaTTof0zktMqgrKLuIew7VSXombnfS5kPof--MM4jWpQrq5Smop6rOCb5cEo5_5o0Ply0TnH-rTkhL23opGD76NB9XZyk9420x3EgiT6r09Pj3oUFTDNnqnBCswfmUkXZpGiA7XztvirYGgS7Zov_OeDsj559LnBF4g0aXg94Eb6KDAZk59cXr7IJHrw7QGEx556wRlBymDazn0-p7D0OyZ4e-qP7dXD-tftf3f27vVlf3taZc5LqjDRVLYL2VphMgqZQdNyA5YKI7LEXPJevJkjIgEjPL-k5IwQzvDOAWa7qofu25U-lGa7T1OcKgpuhGiLMK4NTXjXcbtQ6viuDtExtCt4QfB0IML8WmrEaXtB0G8DaUpJqWS7ENi130Yh_VMaQUbf9xh2C106N2etS7HvoGndCHRg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2859604663</pqid></control><display><type>article</type><title>TRPM2 protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction via modulating autophagy</title><source>PubMed Central (Open access)</source><source>ProQuest - Publicly Available Content Database</source><creator>Yu, Binfeng ; Jin, Lini ; Yao, Xi ; Zhang, Yi ; Zhang, Gensheng ; Wang, Fangqin ; Su, Xinwan ; Fang, Qiuyuan ; Xiao, Liang ; Yang, Yi ; Jiang, Lin-Hua ; Chen, Jianghua ; Yang, Wei ; Lin, Weiqiang ; Han, Fei</creator><creatorcontrib>Yu, Binfeng ; Jin, Lini ; Yao, Xi ; Zhang, Yi ; Zhang, Gensheng ; Wang, Fangqin ; Su, Xinwan ; Fang, Qiuyuan ; Xiao, Liang ; Yang, Yi ; Jiang, Lin-Hua ; Chen, Jianghua ; Yang, Wei ; Lin, Weiqiang ; Han, Fei</creatorcontrib><description>Background: Cisplatin is a widely used anti-tumor agent but its use is frequently limited by nephrotoxicity. Transient receptor potential melastatin 2 (TRPM2) is a non-selective cation channel which is generally viewed as a sensor of oxidative stress, and increasing evidence supports its link with autophagy, a critical process for organelle homeostasis. Methods: Cisplatin-induced cell injury and mitochondrial damage were both assessed in WT and Trpm2- knockout mice and primary cells. RNA sequencing, immunofluorescence staining, immunoblotting and flowcytometry were applied to interpret the mechanism of TRPM2 in cisplatin nephrotoxicity. Results: Knockout of TRPM2 exacerbates renal dysfunction, tubular injury and cell apoptosis in a model of acute kidney injury (AKI) induced by treatment with cisplatin. Cisplatin-caused tubular mitochondrial damage is aggravated in TRPM2-deficient mice and cells and, conversely, alleviated by treatment with Mito-TEMPO, a mitochondrial ROS scavenger. TRPM2 deficiency hinders cisplatin-induced autophagy via blockage of Ca 2+ influx and subsequent up-regulation of AKT-mTOR signaling. Consistently, cisplatin-induced tubular mitochondrial damage, cell apoptosis and renal dysfunction in TRPM2-deficient mice are mitigated by treatment with a mTOR inhibitor. Conclusion: Our results suggest that the TRPM2 channel plays a protective role in cisplatin-induced AKI via modulating the Ca 2+ -AKT-mTOR signaling pathway and autophagy, providing novel insights into the pathogenesis of kidney injury.</description><identifier>ISSN: 1838-7640</identifier><identifier>EISSN: 1838-7640</identifier><identifier>DOI: 10.7150/thno.84655</identifier><language>eng</language><publisher>Sydney: Ivyspring International Publisher</publisher><subject>Research Paper</subject><ispartof>Theranostics, 2023-01, Vol.13 (13), p.4356-4375</ispartof><rights>The author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-b32367a4fe9db6a9399b5da95a01cb096f594f1734a1904e4fb6964d5bda080c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465213/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465213/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,37048,53827,53829</link.rule.ids></links><search><creatorcontrib>Yu, Binfeng</creatorcontrib><creatorcontrib>Jin, Lini</creatorcontrib><creatorcontrib>Yao, Xi</creatorcontrib><creatorcontrib>Zhang, Yi</creatorcontrib><creatorcontrib>Zhang, Gensheng</creatorcontrib><creatorcontrib>Wang, Fangqin</creatorcontrib><creatorcontrib>Su, Xinwan</creatorcontrib><creatorcontrib>Fang, Qiuyuan</creatorcontrib><creatorcontrib>Xiao, Liang</creatorcontrib><creatorcontrib>Yang, Yi</creatorcontrib><creatorcontrib>Jiang, Lin-Hua</creatorcontrib><creatorcontrib>Chen, Jianghua</creatorcontrib><creatorcontrib>Yang, Wei</creatorcontrib><creatorcontrib>Lin, Weiqiang</creatorcontrib><creatorcontrib>Han, Fei</creatorcontrib><title>TRPM2 protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction via modulating autophagy</title><title>Theranostics</title><description>Background: Cisplatin is a widely used anti-tumor agent but its use is frequently limited by nephrotoxicity. Transient receptor potential melastatin 2 (TRPM2) is a non-selective cation channel which is generally viewed as a sensor of oxidative stress, and increasing evidence supports its link with autophagy, a critical process for organelle homeostasis. Methods: Cisplatin-induced cell injury and mitochondrial damage were both assessed in WT and Trpm2- knockout mice and primary cells. RNA sequencing, immunofluorescence staining, immunoblotting and flowcytometry were applied to interpret the mechanism of TRPM2 in cisplatin nephrotoxicity. Results: Knockout of TRPM2 exacerbates renal dysfunction, tubular injury and cell apoptosis in a model of acute kidney injury (AKI) induced by treatment with cisplatin. Cisplatin-caused tubular mitochondrial damage is aggravated in TRPM2-deficient mice and cells and, conversely, alleviated by treatment with Mito-TEMPO, a mitochondrial ROS scavenger. TRPM2 deficiency hinders cisplatin-induced autophagy via blockage of Ca 2+ influx and subsequent up-regulation of AKT-mTOR signaling. Consistently, cisplatin-induced tubular mitochondrial damage, cell apoptosis and renal dysfunction in TRPM2-deficient mice are mitigated by treatment with a mTOR inhibitor. Conclusion: Our results suggest that the TRPM2 channel plays a protective role in cisplatin-induced AKI via modulating the Ca 2+ -AKT-mTOR signaling pathway and autophagy, providing novel insights into the pathogenesis of kidney injury.</description><subject>Research Paper</subject><issn>1838-7640</issn><issn>1838-7640</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkU1LJDEQhpvFBWX04i_IcRHaTTof0zktMqgrKLuIew7VSXombnfS5kPof--MM4jWpQrq5Smop6rOCb5cEo5_5o0Ply0TnH-rTkhL23opGD76NB9XZyk9420x3EgiT6r09Pj3oUFTDNnqnBCswfmUkXZpGiA7XztvirYGgS7Zov_OeDsj559LnBF4g0aXg94Eb6KDAZk59cXr7IJHrw7QGEx556wRlBymDazn0-p7D0OyZ4e-qP7dXD-tftf3f27vVlf3taZc5LqjDRVLYL2VphMgqZQdNyA5YKI7LEXPJevJkjIgEjPL-k5IwQzvDOAWa7qofu25U-lGa7T1OcKgpuhGiLMK4NTXjXcbtQ6viuDtExtCt4QfB0IML8WmrEaXtB0G8DaUpJqWS7ENi130Yh_VMaQUbf9xh2C106N2etS7HvoGndCHRg</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Yu, Binfeng</creator><creator>Jin, Lini</creator><creator>Yao, Xi</creator><creator>Zhang, Yi</creator><creator>Zhang, Gensheng</creator><creator>Wang, Fangqin</creator><creator>Su, Xinwan</creator><creator>Fang, Qiuyuan</creator><creator>Xiao, Liang</creator><creator>Yang, Yi</creator><creator>Jiang, Lin-Hua</creator><creator>Chen, Jianghua</creator><creator>Yang, Wei</creator><creator>Lin, Weiqiang</creator><creator>Han, Fei</creator><general>Ivyspring International Publisher</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230101</creationdate><title>TRPM2 protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction via modulating autophagy</title><author>Yu, Binfeng ; Jin, Lini ; Yao, Xi ; Zhang, Yi ; Zhang, Gensheng ; Wang, Fangqin ; Su, Xinwan ; Fang, Qiuyuan ; Xiao, Liang ; Yang, Yi ; Jiang, Lin-Hua ; Chen, Jianghua ; Yang, Wei ; Lin, Weiqiang ; Han, Fei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-b32367a4fe9db6a9399b5da95a01cb096f594f1734a1904e4fb6964d5bda080c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Binfeng</creatorcontrib><creatorcontrib>Jin, Lini</creatorcontrib><creatorcontrib>Yao, Xi</creatorcontrib><creatorcontrib>Zhang, Yi</creatorcontrib><creatorcontrib>Zhang, Gensheng</creatorcontrib><creatorcontrib>Wang, Fangqin</creatorcontrib><creatorcontrib>Su, Xinwan</creatorcontrib><creatorcontrib>Fang, Qiuyuan</creatorcontrib><creatorcontrib>Xiao, Liang</creatorcontrib><creatorcontrib>Yang, Yi</creatorcontrib><creatorcontrib>Jiang, Lin-Hua</creatorcontrib><creatorcontrib>Chen, Jianghua</creatorcontrib><creatorcontrib>Yang, Wei</creatorcontrib><creatorcontrib>Lin, Weiqiang</creatorcontrib><creatorcontrib>Han, Fei</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Theranostics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Binfeng</au><au>Jin, Lini</au><au>Yao, Xi</au><au>Zhang, Yi</au><au>Zhang, Gensheng</au><au>Wang, Fangqin</au><au>Su, Xinwan</au><au>Fang, Qiuyuan</au><au>Xiao, Liang</au><au>Yang, Yi</au><au>Jiang, Lin-Hua</au><au>Chen, Jianghua</au><au>Yang, Wei</au><au>Lin, Weiqiang</au><au>Han, Fei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TRPM2 protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction via modulating autophagy</atitle><jtitle>Theranostics</jtitle><date>2023-01-01</date><risdate>2023</risdate><volume>13</volume><issue>13</issue><spage>4356</spage><epage>4375</epage><pages>4356-4375</pages><issn>1838-7640</issn><eissn>1838-7640</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>These authors contributed equally to this work.</notes><notes>Competing Interests: The authors have declared that no competing interest exists.</notes><abstract>Background: Cisplatin is a widely used anti-tumor agent but its use is frequently limited by nephrotoxicity. Transient receptor potential melastatin 2 (TRPM2) is a non-selective cation channel which is generally viewed as a sensor of oxidative stress, and increasing evidence supports its link with autophagy, a critical process for organelle homeostasis. Methods: Cisplatin-induced cell injury and mitochondrial damage were both assessed in WT and Trpm2- knockout mice and primary cells. RNA sequencing, immunofluorescence staining, immunoblotting and flowcytometry were applied to interpret the mechanism of TRPM2 in cisplatin nephrotoxicity. Results: Knockout of TRPM2 exacerbates renal dysfunction, tubular injury and cell apoptosis in a model of acute kidney injury (AKI) induced by treatment with cisplatin. Cisplatin-caused tubular mitochondrial damage is aggravated in TRPM2-deficient mice and cells and, conversely, alleviated by treatment with Mito-TEMPO, a mitochondrial ROS scavenger. TRPM2 deficiency hinders cisplatin-induced autophagy via blockage of Ca 2+ influx and subsequent up-regulation of AKT-mTOR signaling. Consistently, cisplatin-induced tubular mitochondrial damage, cell apoptosis and renal dysfunction in TRPM2-deficient mice are mitigated by treatment with a mTOR inhibitor. Conclusion: Our results suggest that the TRPM2 channel plays a protective role in cisplatin-induced AKI via modulating the Ca 2+ -AKT-mTOR signaling pathway and autophagy, providing novel insights into the pathogenesis of kidney injury.</abstract><cop>Sydney</cop><pub>Ivyspring International Publisher</pub><doi>10.7150/thno.84655</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1838-7640
ispartof Theranostics, 2023-01, Vol.13 (13), p.4356-4375
issn 1838-7640
1838-7640
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10465213
source PubMed Central (Open access); ProQuest - Publicly Available Content Database
subjects Research Paper
title TRPM2 protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction via modulating autophagy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T07%3A26%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TRPM2%20protects%20against%20cisplatin-induced%20acute%20kidney%20injury%20and%20mitochondrial%20dysfunction%20via%20modulating%20autophagy&rft.jtitle=Theranostics&rft.au=Yu,%20Binfeng&rft.date=2023-01-01&rft.volume=13&rft.issue=13&rft.spage=4356&rft.epage=4375&rft.pages=4356-4375&rft.issn=1838-7640&rft.eissn=1838-7640&rft_id=info:doi/10.7150/thno.84655&rft_dat=%3Cproquest_pubme%3E2859604663%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-b32367a4fe9db6a9399b5da95a01cb096f594f1734a1904e4fb6964d5bda080c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2859604663&rft_id=info:pmid/&rfr_iscdi=true